Astellas to acquire Ogeda SA

on 02/04/2017 10:36
Acquisition expands Astellas' Late Stage Clinical Pipeline with Fezolinetant
Read more

Ogeda announces fezolinetant as INN and issuance of US patent for ESN364

on 20/12/2016 10:45

Euroscreen announces name change to Ogeda and completion of Series B financing

on 19/10/2016 11:35
New identity reflects Ogeda’s successful transition to GPCR drug discovery & development
Read more